Tocilizumab treatment of COVID-19: relevance of delay in therapy initiation in middle-income countries
This study emphasizes the importance of timely administration of TCZ in COVID-19 pneumonia. Better outcomes were observed when TCZ was administered up to 7.5 days since the onset of symptoms.
Authors
- Ana Filipović (ORCID: https://orcid.org/0000-0003-4334-8982)
- Mihailo Stjepanović (ORCID: https://orcid.org/0000-0003-1787-1438)
- Ivana Milošević (ORCID: https://orcid.org/0000-0002-4331-3328)
- Nikola Mitrović (ORCID: https://orcid.org/0000-0002-0882-7307)
- Tatjana M. Gazibara (ORCID: https://orcid.org/0000-0002-9621-8375)
- Nataša Nikolić (ORCID: https://orcid.org/0000-0002-3902-0901)
- Jelena Dotlić (ORCID: https://orcid.org/0000-0001-9683-9561)
- Branko Beronja (ORCID: https://orcid.org/0009-0008-2097-8731)
- Jelena Simić (ORCID: https://orcid.org/0009-0009-6757-3077)
- Nevena Todorović (ORCID: https://orcid.org/0000-0001-9227-1067)
- Olja Stevanović
Institutions
- University of Belgrade (RS)
- Univerzitetski Klinički Centar Srbije (RS)
Publication Details
- Journal
- The Journal of Infection in Developing Countries
- Published
- 2025-02-28
- DOI
- https://doi.org/10.3855/jidc.19914
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00